Cell-based approach utilizes mass spectrometry for screening GLS1 pathway activities, suggesting efficacy.
Acoustic ejection mass spectrometry (Echo-MS) is a viable biochemical screening platform enabling direct detection of biologically relevant enzymatic activities with throughput approaching or meeting the cycle time of conventional optical readouts. Here, we present a cell-based in situ approach for the application of an MS-based screening technique using a well-characterized isotope-enriched metabolite as a tracer of cellular activity through the glutaminase 1 (GLS1) pathway. This assay was validated as a proof-of-concept screen in biochemical and primary human cellular high-throughput screening (HTS) formats using known inhibitors of the human GLS1 target. The results generated displayed an excellent alignment between biochemical and cellular potencies. The direct high-throughput mass spectrometry activity assay presented has promise as a cell-based screening approach for profiling of physiologically relevant adherent cells, eliminating the need for detection antibodies or other labeling methods.
No takes yet. Share an insight, caveat, or question.
Downes et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: